StockData
NEXGEL, Inc. logo

NEXGEL, Inc. (NXGLW) stock analysis

NXGLWNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as NXGL
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026Score 6/3072% below fair value
$0.01+0.00 (0.00%)

Close on Oct 30, 2026Market cap $34.21MP/E –Yield –

StockData Score

Prices as of Oct 30, 2026How the score works

Value2Growth1Performance1Health2Dividend0

Weak6 of 30 checks passed

Nexgel passes 6 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
2/6
Growth
1/6
Past performance
1/6
Financial health
2/6
Dividend
0/6

What stands out

  • Margin of safety over 20%

    The price is 71.5% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $3.51 is below our fair value estimate of $12.33.

  • Low debt

    Debt is 8.8% of shareholders' equity, under the 40% we consider low.

  • Revenue growing 10%+ a year

    Revenue grew 77.3% a year over the last three fiscal years.

What to watch

  • Return on equity under 15%

    Return on equity was -129% over the last twelve months and averaged -58.4% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -91.0%, below the 10% that usually covers the cost of capital.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -733% of total debt; we look for at least 20%.

  • Elevated bankruptcy risk

    The Altman Z-score is -0.97; above 3 is the safe zone and below 1.8 the distress zone.

Valuation2/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Nexgel's price-to-book of 6.91 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.11.

  • Trading below fair value

    The share price of $3.51 is below our fair value estimate of $12.33.

  • Margin of safety over 20%

    The price is 71.5% below fair value, more than the 20% cushion we look for.

Growth1/6

  • Revenue growing 10%+ a year

    Revenue grew 77.3% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew 3.4% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 10.4%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin slipping

    Gross margin was 35.1% over the last twelve months, against 40.1% a year earlier.

Past performance1/6

  • Return on equity under 15%

    Return on equity was -129% over the last twelve months and averaged -58.4% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -91.0%, below the 10% that usually covers the cost of capital.

  • Return on equity below the industry

    Nexgel's return on equity of -129% is below the Surgical, Medical, and Dental Instruments and Supplies median of -35.2%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -51.3% over the last twelve months, against a 5-year average of -130%.

  • Net margin below the industry

    Nexgel's net margin of -51.3% is below the Surgical, Medical, and Dental Instruments and Supplies median of -15.8%.

Financial health2/6

  • Low debt

    Debt is 8.8% of shareholders' equity, under the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 361% five years ago to 8.8%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -733% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets don't cover short-term debts

    Current assets are 0.43 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -0.97; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Nexgel has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$12.33

The share price is 72% below this estimate.

20%+ below
Near fair value
20%+ above
$3.51Price$12.33Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B12.0×40.9×3.1×$6.0950%
P/S15.0×67.8×2.7×$18.5750%
Fair value$12.33100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 40.9
  • Surgical, Medical, and Dental Instruments and Supplies median 3.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$870.25K
Value traded per 1% price move
$17.33K

Downside

High risk

Typical loss in a bad month
48.8%
Volatility (annualized)
127%
Sharpe ratio, 1 year
-0.76
Beta to the S&P 500 (5Y)
0.61

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2017 to 2025

Gross margin

39.5%+82.7 pts over 5 years

Operating margin

-29.3%+306.0 pts over 5 years

Net margin

-26.3%+309.6 pts over 5 years